Dr Reddy's Laboratories vs Aurobindo Pharma: Which Stock Should You Track

Dr Reddy's Laboratories vs Aurobindo Pharma is a comparison investors search for because the two companies represent genuinely different positions within Pharmaceuticals. This Dr Reddy's Laboratories vs Aurobindo Pharma breakdown goes beyond generic labels and looks at real numbers: reach, products, the latest results each company has declared, and how each stock is positioned today. Understanding Dr Reddy's Laboratories vs Aurobindo Pharma this way is more useful than a surface-level label, because it shows where each company actually stands rather than how it describes itself.

Dr Reddy's Laboratories vs Aurobindo Pharma: Reach and Market Position

In the Dr Reddy's Laboratories vs Aurobindo Pharma comparison, Dr Reddy's Laboratories stands out for a Hyderabad-based global pharmaceutical major with a diversified footprint across North America, Europe, Emerging Markets and India. This scale gives Dr Reddy's Laboratories a distinct position within Pharmaceuticals that shapes how it competes.

Click Here – Get Free Investment Predictions

Aurobindo Pharma, on the other hand, is built around a Hyderabad-based drugmaker exporting to over 150 countries through 27 global manufacturing and packing facilities. Comparing Dr Reddy's Laboratories vs Aurobindo Pharma on reach alone shows two different growth strategies, not a single verdict.

Dr Reddy's Laboratories vs Aurobindo Pharma: Key Products and Business Mix

Dr Reddy's Laboratories's business runs on generic drugs, biosimilars, active pharmaceutical ingredients, and branded formulations. This product mix is central to any Dr Reddy's Laboratories vs Aurobindo Pharma comparison, since it explains where each company's revenue actually comes from.

Aurobindo Pharma instead leans on generic drugs, active pharmaceutical ingredients, and biocatalysts through its AuroZymes division. The Dr Reddy's Laboratories vs Aurobindo Pharma product comparison shows these are genuinely different businesses, not just different brand names in the same category.

Dr Reddy's Laboratories vs Aurobindo Pharma: Latest Results

Looking at real numbers rather than claims, Dr Reddy's Laboratories's latest disclosed results show Q1 FY27 consolidated net profit of around Rs 1,290 crore, down about 8% YoY, on revenue of about Rs 7,650-8,071 crore, as North American generic sales faced pricing pressure on key molecules including lenalidomide; Emerging Markets revenue grew 31% YoY and India grew 17% YoY. This is the clearest evidence available for the Dr Reddy's Laboratories vs Aurobindo Pharma comparison on Dr Reddy's Laboratories's side.

Aurobindo Pharma's latest disclosed results show FY2025 (latest full-year figures available) revenue of Rs 31,724 crore; prior-year quarterly results have shown swings tied to US sales and destocking cycles, with profit ranging from double-digit growth to double-digit declines across recent quarters. Weighing Dr Reddy's Laboratories vs Aurobindo Pharma on actual results, rather than headline positioning, is what separates a useful comparison from a generic one.

Compare Dr Reddy's Laboratories and Aurobindo Pharma Fundamentals on the Univest Screener

Dr Reddy's Laboratories vs Aurobindo Pharma: Stock and Valuation

On the market side, Dr Reddy's Laboratories is described as: Shares touched a 52-week low following the Q1 FY27 results per market reports. Aurobindo Pharma is described as: Holds USFDA, UK MHRA and other major regulatory approvals across its facility network. The Dr Reddy's Laboratories vs Aurobindo Pharma valuation gap often reflects how the market is pricing each company's growth and risk profile differently.

Dr Reddy's Laboratories vs Aurobindo Pharma: Quick Comparison Table

Parameter	Dr Reddy's Laboratories	Aurobindo Pharma
Sector	Pharmaceuticals	Pharmaceuticals
Market position	a leading Indian pharmaceutical company with a diversified global generics and biosimilars footprint	a leading Indian generics exporter with a global manufacturing footprint
Reach	a Hyderabad-based global pharmaceutical major with a diversified footprint across North Am	a Hyderabad-based drugmaker exporting to over 150 countries through 27 global manufacturin
Latest results	Q1 FY27 consolidated net profit of around Rs 1,290 crore, down about 8% YoY, on revenue of about Rs	FY2025 (latest full-year figures available) revenue of Rs 31,724 crore; prior-year quarterly results

Conclusion

Dr Reddy's Laboratories vs Aurobindo Pharma ultimately comes down to two companies solving similar problems in different ways. Dr Reddy's Laboratories brings a leading Indian pharmaceutical company with a diversified global generics and biosimilars footprint, while Aurobindo Pharma brings a leading Indian generics exporter with a global manufacturing footprint. Investors weighing Dr Reddy's Laboratories vs Aurobindo Pharma should track both companies' upcoming results and valuation gap rather than picking a side on reputation alone. This Dr Reddy's Laboratories vs Aurobindo Pharma breakdown is a starting point, not a final verdict.

Download the Univest iOS App or Univest Android App to track Dr Reddy's Laboratories and Aurobindo Pharma live price and get daily stock recommendations.

Frequently Asked Questions

What is the main difference between Dr Reddy's Laboratories and Aurobindo Pharma?

Ans. The main difference in the Dr Reddy's Laboratories vs Aurobindo Pharma comparison lies in scale and business mix. Dr Reddy's Laboratories is built on a leading Indian pharmaceutical company with a diversified global generics and biosimilars footprint, while Aurobindo Pharma is positioned around a leading Indian generics exporter with a global manufacturing footprint.

How do Dr Reddy's Laboratories and Aurobindo Pharma's latest results compare?

Ans. Comparing Dr Reddy's Laboratories vs Aurobindo Pharma on latest disclosed results: Dr Reddy's Laboratories reported Q1 FY27 consolidated net profit of around Rs 1,290 crore, down about 8% YoY, on revenue of about Rs 7,650-8,071 crore, as North American gen, while Aurobindo Pharma reported FY2025 (latest full-year figures available) revenue of Rs 31,724 crore; prior-year quarterly results have shown swings tied to US sales and .

What sector do Dr Reddy's Laboratories and Aurobindo Pharma operate in?

Ans. Dr Reddy's Laboratories operates in Pharmaceuticals and Aurobindo Pharma operates in Pharmaceuticals. Even where the sectors overlap, the Dr Reddy's Laboratories vs Aurobindo Pharma comparison shows different product mixes and market positions.

Should I invest in Dr Reddy's Laboratories or Aurobindo Pharma?

Ans. Both Dr Reddy's Laboratories and Aurobindo Pharma have distinct strengths within their space. Investors comparing Dr Reddy's Laboratories vs Aurobindo Pharma should review the latest quarterly results, valuation and their own risk profile, and consult a financial advisor before deciding.

What are the key products of Dr Reddy's Laboratories?

Ans. Dr Reddy's Laboratories's key products and business lines include generic drugs, biosimilars, active pharmaceutical ingredients, and branded formulations.

What are the key products of Aurobindo Pharma?

Ans. Aurobindo Pharma's key products and business lines include generic drugs, active pharmaceutical ingredients, and biocatalysts through its AuroZymes division.

How do Dr Reddy's Laboratories and Aurobindo Pharma compare on market position?

Ans. On market position, Dr Reddy's Laboratories holds a leading Indian pharmaceutical company with a diversified global generics and biosimilars footprint, while Aurobindo Pharma holds a leading Indian generics exporter with a global manufacturing footprint. The Dr Reddy's Laboratories vs Aurobindo Pharma comparison shows both companies lead in different ways rather than one being universally ahead.